ストックスクリーナーアプリを入手
2.11
6.57%
0.13
アフターアワーズ：
2.05
-0.06
-2.84%
Dare Bioscience Inc (DARE) 最新ニュース
Dare Bioscience (DARE) Holds Near Support After Marginal DeclineSector ETF Flow - newsline.com
Daré Bioscience Shareholders Back Governance and Capital Plans - The Globe and Mail
Daré Bioscience (NASDAQ: DARE) OKs equity line and boosts incentive plan shares - Stock Titan
Dare Bioscience (DARE) director receives 10,000 stock option grant - Stock Titan
Director Susan L. Kelley receives 10,000 Dare Bioscience (DARE) stock options - Stock Titan
Director at Dare Bioscience (NASDAQ: DARE) receives 10,000 stock options grant - Stock Titan
Director Gregory Matz receives 10,000 Dare Bioscience (DARE) stock options - Stock Titan
Dare Bioscience (DARE) director receives 10,000 stock options at $2.03 strike - Stock Titan
Dare Bioscience Inc Annual Shareholders Meeting Transcript - GuruFocus
Dare Bioscience Company Profile & Introduction - Moomoo
Daré Bioscience to launch vaginal probiotic product - Investing.com
Daré Bioscience to launch vaginal probiotic product By Investing.com - Investing.com South Africa
Daré Bioscience Announces the Upcoming Launch of Flora Sync LF5™ Vaginal Probiotic Capsules - The Manila Times
New vaginal probiotic aims to support comfort — with 30% launch discount - Stock Titan
DARE Stock Price, Quote & Chart | DARE BIOSCIENCE INC (NASDAQ:DARE) - ChartMill
Dare Bioscience (DARE) Dips 2.15%, Hovers Above Key Support at $2.17ETF NAV Deviation - newsline.com
Dare Bioscience (DARE) Edges Higher Amid Steady Support LevelsThematic ETF Flow - The Legal Advocate
Daré Bioscience reports interim phase 3 data for Ovaprene By Investing.com - Investing.com Nigeria
Dare Bioscience (DARE) Secures Final $1M Grant from NIH for HPV Treatment - GuruFocus
Daré Bioscience receives second $1M NIH funding tranche - Investing.com UK
Daré Bioscience receives second $1M NIH funding tranche By Investing.com - Investing.com South Africa
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer - The Manila Times
Press Release: Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, Its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer - Moomoo
Dare Bioscience Inc (DARE) Stock Price, Quote, News & History - Benzinga
Earnings call transcript: Dare Bioscience outlines liquidity and revenue plans in Q1 2026 By Investing.com - Investing.com South Africa
Earnings call transcript: Dare Bioscience outlines liquidity and revenue plans in Q1 2026 - Investing.com
Dare Bioscience, Inc.Common Stock (NQ: DARE - The Chronicle-Journal
Maxim Group Maintains Dare Bioscience(DARE.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies - Sahm
Dare Bioscience completes closing of Regulation A equity offering By Investing.com - Investing.com Australia
Dare Bioscience (DARE) Launches Phase 2 Study for DARE-HPV Treat - GuruFocus
Daré Bioscience Completes Regulation A Investor Unit Offering - TipRanks
Dare Bioscience completes closing of Regulation A equity offering - Investing.com
Daré Bioscience (NASDAQ: DARE) issues 50,000 preferred unit package - Stock Titan
Dare Bioscience Q3 2025 Earnings Preview - MSN
Daré Bioscience begins phase 2 trial for HPV treatment By Investing.com - Investing.com South Africa
Daré Bioscience initiates phase 2 study of Dare-HPV - marketscreener.com
Daré Bioscience Initiates Phase 2 Study Of Dare-Hpv - TradingView
Daré Bioscience begins phase 2 trial for HPV treatment - Investing.com
Daré Bioscience Initiates Phase 2 Study for DARE-HPV, Potential First Pharmacologic Treatment for High-Risk HPV Infection - Quiver Quantitative
6M women get high-risk HPV yearly; new trial tests first potential drug - Stock Titan
Daré Bioscience, Inc. (NASDAQ:DARE) Q1 2026 Earnings Call Transcript - Insider Monkey
H.C. Wainwright Maintains Dare Bioscience(DARE.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Q1 2026 Dare Bioscience Inc Earnings Call Transcript - GuruFocus
Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update - Sahm
Dare Bioscience Inc (DARE) Q1 2026 Earnings Call Highlights: Str - GuruFocus
Daré Bioscience Releases Q1 2026 Financial Results - AlphaStreet
Daré Bioscience (DARE) Reports Positive Developments and Financi - GuruFocus
Daré Bioscience targets Ovaprene Phase III to reach 2,500 exposure cycles in 2026 as Flora Sync LF5 revenue is expected to begin in June - MSN
Dare Bioscience (DARE) Q1 2026: EPS -$0.20 vs -$0.27 est (beat); - GuruFocus
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):